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Introduction
HDL-cholesterol levels are reduced in obesity, especially in those 
individuals with features of the metabolic syndrome (1, 2). The 
metabolic syndrome is accompanied by adipose tissue (AT) (3, 4) 
and systemic inflammation (5). Because HDL-cholesterol levels 
can drop following acute inflammatory stimuli (6), it has been sug-
gested that low HDL cholesterol levels associated with obesity are 
a result of chronic, low-grade inflammation (6). HDL has several 
functions, including mediation of reverse cholesterol transport 
(7) and inhibition of inflammation (8–11), oxidation (12, 13), and 
endothelial activation (14, 15).
We recently showed that apolipoprotein A-I (apoA-I) and HDL 
derived from normal human subjects strongly inhibited palmi-
tate-induced chemotactic factor expression in adipocytes in vitro 
and that overexpression of human apoA-I led to a reduction of 
macrophage accumulation and inflammatory gene expression in 
AT of mice fed a high-fat, proinflammatory diet (16). The ability 
of apoA-I and HDL to inhibit inflammation in adipocytes resulted 
from disruption of lipid rafts (LRs) and reduction of plasma mem-
brane cholesterol; it was also associated with a reduction in palmi-
tate-induced generation of ROS (16).
HDL can become dysfunctional during inflammation (17–20). 
For example, HDL from acutely inflamed human subjects and 
rabbits (21), and from subjects with inflammatory disorders such 
as rheumatoid arthritis and systemic lupus erythematosus (SLE) 
(22), loses its antiinflammatory properties. Plasma levels of serum 
amyloid A (SAA) increase during acute and chronic inflammation 
(23). The SAA family of proteins are major acute-phase reactants 
in mammals (23). Circulating levels of the inducible forms of SAA, 
SAA1, and SAA2, which are produced mainly by the liver, increase 
dramatically after acute inflammatory stimuli (23). Since SAA1 
and SAA2 are transported in plasma mainly on HDL (24–26), we 
investigated whether the presence of SAA on HDL affects its abil-
ity to inhibit palmitate-induced inflammation in adipocytes.
SAA-containing HDL has been shown to have reduced ability to 
facilitate cholesterol efflux from macrophages (26–29). The inability 
of HDL from patients with chronic renal failure to inhibit inflamma-
tion in smooth muscle cells has been attributed to the presence of 
SAA on HDL particles (30). HDL also might become dysfunctional 
due to oxidative damage. Myeloperoxidase (MPO) generates HOCl, 
which oxidizes specific tyrosine and methionine residues on apoA-I, 
thereby impairing apoA-I–mediated cholesterol efflux (31–33). HDL 
has been proposed to become oxidized in the milieu of the artery 
wall (34–36) but might also be oxidized in AT (37–39). Although the 
presence of SAA on HDL has been reported to impair HDL’s antioxi-
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matory function (Supplemental Figure 1). To exclude the possibility 
that exposure of adipocytes to palmitate increased the phospholipid 
content of the plasma membrane, thereby acting as a sink for choles-
terol, total phospholipid content of the adipocyte plasma membrane 
was measured and found to be unaltered by either palmitate or HDL 
exposure (Supplemental Figure 2). These results imply that HDL 
isolated from mice following an acute inflammatory stimulus loses 
its ability to facilitate cholesterol efflux, disrupt LRs, reduce the gen-
eration of palmitate-induced ROS, and inhibit palmitate-induced 
inflammatory gene expression.
SAA plays an important role in reducing the antiinflammatory 
effect of HDL. To investigate the effects of reducing levels of SAA in 
inflammatory HDL, HDL was isolated from AgNO3-injected con-
trol (C57BL/6) and SAA-DKO (Saa1.1–/–/Saa.2.1–/–) mice (43, 44). It 
has been reported that HDL isolated from inflamed SAA-DKO mice 
has trace amount of SAA (45) — presumably SAA4, the constitutive 
form of SAA — while inflamed HDL from C57BL/6 mice contains 
an abundance of SAA1.1 and SAA2.1 (45). In confirmation of these 
findings, we observed that the SAA protein concentrations in HDL 
from PBS- and AgNO3-injected C57BL/6 mice were 31 ± 2 μg/mg 
and 362 ± 35 μg/mg HDL protein (n = 6), respectively, whereas the 
SAA protein concentrations in HDL from PBS- and AgNO3-injected 
SAA-DKO mice were 24 ± 2 μg/mg and 35 ± 3 μg/mg HDL protein 
(n = 5), respectively. We first determined whether HDL from these 
4 groups of mice could inhibit the expression of chemotactic fac-
tor and inflammatory genes in adipocytes subsequent to palmitate 
treatment. HDL from PBS-injected C57BL/6 and SAA-DKO mice 
inhibited palmitate-induced Saa3, Ccl2, Il1β, and Il6 gene expres-
sion, whereas HDL from AgNO3-injected C57BL/6 mice totally 
lost its inhibitory effect on palmitate-induced inflammatory gene 
expression. Importantly, HDL from AgNO3-injected SAA-DKO 
mice showed partial inhibition of palmitate-induced inflammatory 
gene expression (Figure 2A). Since the concentration of apoA-I as 
a percent of total HDL protein is reduced in HDL from AgNO3- 
injected C57BL/6 mice, we performed additional experiments in 
which more total HDL protein was added to provide equivalent 
amounts of apoA-I. These results showed the same pattern as when 
equal amounts of total HDL protein were added (data not shown). 
We also matched the concentration of HDL on the basis of particle 
number; the results showed the same pattern (data not shown).
HDL from PBS-injected C57BL/6 and SAA-DKO mice and HDL 
from AgNO3-injected SAA-DKO mice also decreased the cholesterol 
content of plasma membranes in 3T3-L1 adipocytes, whereas HDL 
from AgNO3-injected C57BL/6 mice did not (Figure 2B). Consistent 
with these effects on plasma membrane cholesterol levels, HDL 
from PBS-injected C57BL/6 and SAA-DKO mice, and HDL from 
AgNO3-injected SAA-DKO mice, increased cholesterol efflux (Fig-
ure 2C). The ability of HDL from AgNO3-injected SAA-DKO mice to 
facilitate cholesterol efflux was restored, compared with HDL from 
AgNO3-injected C57BL/6 mice (Figure 2C). We previously have 
shown that inflammatory gene expression was inversely related to 
the content of LRs and to ROS generation and could be reversed 
by incubation with HDL from normal subjects (16). Therefore, we 
tested the effect of HDL from AgNO3-injected mice in this study. 
LRs and ROS generation were decreased by exposure of adipocytes 
to control HDL from PBS-injected C57BL/6 mice. Similar effects 
were observed with HDL from SAA-DKO mice. However, LRs and 
dative functionality (40), little is known regarding the effect of HDL 
oxidation on its antiinflammatory properties.
The purpose of the present study was to determine whether 
HDL from inflamed mice and humans loses its ability to inhibit 
palmitate-induced inflammation and to facilitate cholesterol 
efflux in adipocytes, and if so, whether the increased content of 
SAA in HDL or oxidative damage of apoA-I accounts for these 
changes. Our findings demonstrate that HDL from (i) mice with 
silver nitrate–induced (AgNO3-induced) acute inflammation, (ii) 
mice with obesity-induced chronic inflammation, and (iii) human 
subjects with inflammation and SLE were dysfunctional with 
respect to inhibition of palmitate-induced adipocyte inflamma-
tion, and that SAA could account for part of this impairment.
Results
HDL from AgNO3-injected mice exhibits reduced ability to inhibit 
both palmitate-induced adipocyte inflammation and ROS generation 
and to stimulate cholesterol efflux from adipocytes. We previously 
showed that apoA-I and HDL from normal human subjects dis-
rupted LRs, reduced plasma membrane cholesterol content, and 
reduced palmitate-induced ROS generation and monocyte che-
motactic factor expression in 3T3-L1 adipocytes (16). However, it 
is unknown whether these antiinflammatory properties are altered 
when the HDL is derived from subjects with evidence of systemic 
inflammation. To determine the effects of sterile inflammation on 
HDL function, we isolated HDL from C57BL/6 mice that had been 
injected with AgNO3 24 hours earlier. Although control HDL from 
PBS-injected mice blocked the increase of Saa3, Ccl2, Il1β, and Il6 
gene expression induced by palmitate in a dose-dependent manner, 
this effect was lost when adipocytes were preexposed to HDL from 
AgNO3-injected mice (Figure 1A). HDL from AgNO3-injected mice 
also elicited reduced cholesterol efflux from adipocytes compared 
with control HDL (Figure 1B). To determine whether exposure of 
cells to HDL from AgNO3-injected mice disrupts LRs, LRs were visu-
alized using Alexa Fluor 594 cholera toxin subunit β (CTB), which 
selectively binds to LRs in the plasma membrane (41). Exposure 
of adipocytes to palmitate increased CTB-stained LRs compared 
with controls not exposed to palmitate, and preexposure to control 
HDL reduced LRs (Figure 1C). However, HDL from AgNO3-injected 
mice did not reduce palmitate-stimulated LRs to the same extent 
as control HDL (Figure 1C). Next, we evaluated whether HDL from 
AgNO3-injected mice affected palmitate-induced ROS generation. 
While control HDL suppressed palmitate-induced ROS generation, 
as described previously (16), HDL from AgNO3-injected mice did 
not block ROS generation (Figure 1D). We found similar results using 
other types of adipocytes, such as differentiated mouse embryonic 
fibroblasts (MEFs) and human adipocytes from subjects with the 
Simpson-Golabi-Behmel syndrome (SGBS), a rare X-linked disor-
der that can cause craniofacial, skeletal, cardiac, and renal abnor-
malities and is characterized by an increase in weight, height, or 
head circumference (ref. 42 and data not shown). Changes in the 
properties of HDL could not be accounted for by alteration of the 
lipoprotein’s free cholesterol or phospholipid content, since these 
did not change after injection of AgNO3 (Supplemental Figure 1; 
supplemental material available online with this article; doi:10.1172/
JCI83475DS1). Moreover, removal of free cholesterol from HDL 
with methyl-β-cyclodextrin (mβCD) did not affect HDL’s antiinflam-
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by translocation of TLR4 into LRs (48). However, whether HDL 
can block this TLR4-mediated response is unknown. To investigate 
whether TLR4 translocation to LRs following exposure to palmi-
tate could be inhibited by preexposure of adipocytes to HDL, and 
whether this would be affected by presence of SAA, we used HDL 
from AgNO3-injected C57BL/6 and SAA-DKO mice. Prior to expo-
sure of adipocytes to palmitate, TLR4’s presence was confined to 
non-LR fractions of the plasma membrane. Following palmitate 
exposure, TLR4 translocated from non-LR fractions to LR fractions 
ROS generation were not inhibited by exposure of cells to HDL 
from AgNO3-injected C57BL/6 mice, whereas HDL from AgNO3- 
injected SAA-DKO mice partially blocked LRs (Figure 2D) and ROS 
generation (Figure 2E). These results indicate that the absence of 
SAA in HDL from mice with sterile inflammation induced by the 
injection of AgNO3 causes a partial restoration of HDL’s antiinflam-
matory properties on adipocytes.
Activation of TLR4 by LPS and certain free fatty acids can trig-
ger cellular inflammatory responses (46, 47) and is accompanied 
Figure 1. HDL from AgNO3-injected 
mice loses its ability to inhibit 
palmitate-induced adipocyte 
inflammation, to stimulate cho-
lesterol efflux, and to suppress 
ROS generation by adipocytes. 
(A–D) HDL was isolated from the 
plasma of AgNO3- or PBS-injected 
C57BL/6 mice. 3T3-L1 adipocytes 
were preexposed to HDL (indicated 
concentration [A and B] or 50 μg 
protein/ml [C and D]) for 6 hours, 
after which the HDL was removed, 
the cells were washed, and the 
adipocytes were incubated with 
or without palmitate (250 μmol/l) 
for 24 hours prior to measurement 
of Saa3, Ccl2, Il1β, and Il6 gene 
expression (A), cholesterol efflux 
(B), LRs (C), and ROS generation 
(D) as described in Methods. 
Results are plotted as the mean 
fluorescent intensity of each  
sample on the vertical axis  
(C and D). Data represent mean ± 
SD. Data are representative of at 
least 3 independent experiments. 
*P < 0.001 vs. control mouse HDL, 
**P < 0.001 vs. palmitate. ANOVA 
and Bonferroni post-hoc test.
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from AgNO3-injected SAA-DKO mice, TLR4 did not translocate to 
LR fractions following palmitate exposure (Figure 2F, bottom 2 
panels). These results are consistent with the results of cholesterol 
efflux and LRs from HDL from AgNO3-injected SAA-DKO mice 
(Figure 2F, top 2 panels). This effect was inhibited by preexposure 
of the cells to HDL from PBS-injected C57BL/6 mice but not by 
preexposure to HDL from AgNO3-injected C57BL/6 mice (Figure 
2F, middle 2 panels). However, when cells were preexposed to HDL 
Figure 2. HDL from AgNO3-injected SAA-DKO mice retains part of its antiinflammatory effect on adipocytes. HDL was isolated from the plasma of 
AgNO3- or PBS-injected C57BL/6 and SAA-DKO mice. 3T3-L1 adipocytes were treated as described in the legend to Figure 1. Saa3, Ccl2, Il1β, and Il6 gene 
expression (A), plasma membrane cholesterol content (B), cholesterol efflux (C), LR content (D), ROS generation (E), and TLR4 translocation to LRs (F) 
were analyzed. An antibody to caveolin 1 (CAV1) was used to stain LRs. Fractions 7–9 contain LRs, and fractions 1 –4 are non–LR-containing fractions. 
Data represent mean ± SD. Data are representative of at least 3 independent experiments. *P < 0.001 vs. C57BL/6 (AgNO3) HDL, **P < 0.001 vs. C57BL/6 
(control) HDL. ANOVA and Bonferroni post-hoc test.
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Figure 3. SAA-enriched HDL partly loses its antiinflammatory effect on adipocytes. (A–E) 3T3-L1 adipocytes were preexposed for 6 hours to human HDL 
or human HDL isolated after exposure to lentiviral-transduced 293 HEK cells, as described in Methods. HDL concentration was as indicated (A and B) or 50 
μg protein/ml (C and D). Thereafter, adipocytes were treated as described in the legend to Figure 1. Saa3, Ccl2, Il1β, and Il6 gene expression (A); cholesterol 
efflux to human, control, and SAA2-HDL (B); LR content (C); ROS generation (D); and TLR4 translocation to LRs (E). An antibody to caveolin 1 (CAV1) was 
used to stain LRs. Fractions 7–9 contain LRs, and fractions 1–4 are non–LR-containing fractions. Data represent mean ± SD. Data are representative of at 
least 3 independent experiments. *P < 0.001 vs. control-HDL, **P < 0.001 vs. SAA2-HDL. ANOVA and Bonferroni post-hoc test.
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and indicate that the absence of SAA in HDL from mice with sterile 
inflammation induced by AgNO3 injection causes a partial restora-
tion of HDL’s antiinflammatory properties on adipocytes.
Conversely, to test whether increasing the SAA content in HDL 
would have the opposite effect, we incorporated mouse SAA2.1 into 
HDL by exposing normal human HDL to HEK 293 cells transduced 
with a lentivirus encoding mouse SAA2.1 protein. After exposure of 
HDL to these cells for 24 hours, HDL was reisolated from the con-
ditioned media and had a strong SAA band visible on SDS-PAGE, 
compared with several control HDL preparations (Supplemental 
Figure 3). This reisolated HDL preparation (termed SAA2-HDL) 
had 145 ± 5 μg SAA/mg HDL protein (n = 5); all other HDL con-
trols had no measurable SAA. Reisolated HDL that was exposed to 
HEK 293 cells alone without lentiviral transduction (control HDL), 
reisolated HDL that was exposed to mock-transduced HEK 293 
cells (mock-HDL), and normal human HDL all inhibited palmitate- 
induced Saa3, Ccl2, Il1β, and Il6 gene expression (Figure 3A). How-
ever, SAA2-HDL partially lost its ability to inhibit palmitate-induced 
inflammatory gene expression, although the loss of inhibition was 
not as great as for HDL from AgNO3-injected C57BL/6 mice (Fig-
ure 3A). Also, human HDL and control HDL dose-dependently 
increased cholesterol efflux, while SAA2-HDL elicited less choles-
terol efflux (Figure 3B). Consistent with the findings with inflamma-
tory gene expression, LRs (Figure 3C) and ROS generation (Figure 
3D) were decreased by all 3 control HDL preparations relative to 
palmitate alone, while SAA2-HDL partially blocked CTB-stained 
LRs (Figure 3C) and ROS generation (Figure 3D).
To investigate the effect of increasing SAA in control HDL on 
TLR4, we used HDL that had been enriched in its content of SAA 
(SAA2-HDL). Following palmitate exposure, TLR4 translocated 
Figure 4. HDL from AgNO3-injected mice colocalizes with the adipocyte cell surface. (A) HDL from PBS- and AgNO3-injected C57BL/6 mice was labeled 
with DiI (red). After exposure to these HDL preparations (50 μg protein/ml) for 6 hours, 3T3-L1 adipocytes were fixed in 2% formalin for 5 minutes. To 
distinguish the outside of cells from intracellular sites, the cell surface–associated ECM was stained with Alexa Fluor 488–conjugated WGA (green). Cell 
nuclei were counterstained with DAPI (blue). Cell morphology was shown by phase-contrast photography (left panels). Merged fluorescence (overlay) 
is shown in yellow. Original magnification, ×400. When the cell surface–associated ECM of 3T3-L1 adipocytes was digested with chondroitin ABC lyase 
and heparitinase for 1 hour prior to exposure to HDL, colocalization of HDL from AgNO3-injected mice with the cell surface (row 2, column 5) was lost and 
resulted in a similar distribution of dye to that seen with control HDL (row 3, column 5). (B and C) Enzyme digestion of the proteoglycans in the ECM also 
restored the impaired cholesterol efflux observed with HDL from AgNO3-injected mice (B) and Saa3 gene expression (C). Representative fluorescence 
images of 3 independent experiments are shown. Data represent mean ± SD. Data are representative of at least 3 independent experiments. *P < 0.001 vs. 
C57BL/6 HDL (AgNO3), **P < 0.001 vs. AgNO3-HDL. ANOVA and Bonferroni post-hoc test.
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from non-LR to LR fractions (Figure 3E, top 2 panels). This effect 
was inhibited by preexposure of the cells to control HDL but was 
restored by exposure to SAA2-HDL (Figure 3E, bottom 2 panels). 
These results indicate that loading SAA into HDL causes a partial 
loss of HDL’s antiinflammatory effect on adipocytes, consistent 
with changes in translocation of TLR4 to the LR fractions in the 
plasma membrane.
Since we hypothesized that the increased SAA content in HDL 
impairs its antiinflammatory function, we investigated whether 
HDL antiinflammatory function was restored as SAA concentra-
tion returned to baseline following the injection of AgNO3. HDL’s 
ability to inhibit palmitate-induced inflammatory gene expression 
was partially restored 96 hours after AgNO3 injection and fully 
restored by 7 days, consistent with changes in its SAA content 
(Supplemental Figure 4).
The presence of SAA on HDL blocks its access to the adipocyte 
cell membrane. We previously have shown that the presence of 
SAA in HDL enhances its ability to bind to biglycan (49) and that 
apoA-I and SAA are colocalized in the extracellular matrix (ECM) 
of atherosclerosis lesion (50). Moreover, we also have shown that 
adipocytes produce large amounts of ECM when they become 
hypertrophic (51). Therefore, it is plausible that the presence of 
SAA in HDL could cause the lipoprotein to bind to the ECM of adi-
pocytes. To explore potential mechanisms by which SAA impairs 
the antiinflammatory properties of HDL, we tested the hypothesis 
that the presence of SAA in HDL particles facilitates trapping of 
HDL by cell surface–associated ECM, thereby limiting its ability 
to facilitate cholesterol efflux and any downstream effects. For 
these experiments, we stained HDL with 1,1′-dioctadecyl-3,3,3′,3′- 
tetramethylindocarbocyanine perchlorate (DiI) and the cell sur-
face–associated ECM with wheat germ agglutinin (WGA). After 
exposure of adipocytes to DiI-stained control HDL, the cytosol 
was stained with DiI, which did not colocalize with the Alexa Fluor 
488–WGA ECM staining (Figure 4A, top row). It is known that 
cholesterol and other lipids can transfer between HDL and cells 
in a bidirectional manner, mediated by the scavenger receptor B-I 
(SRB-I) or by simple diffusion (52, 53). This is consistent with our 
finding that DiI from control HDL can contact the plasma mem-
brane and enter the cytosol of adipocytes. On the contrary, after 
exposure of cells to HDL labeled with DiI from AgNO3-injected 
mice, the DiI staining colocalizes with cell surface–associated 
ECM staining (Figure 4A, middle row). This suggests that HDL 
labeled with DiI from AgNO3-injected mice can be trapped in the 
cell surface–associated ECM of adipocytes and not be able to ade-
quately contact the plasma membrane. Digestion of the ECM with 
chondroitin ABC lyase and heparitinase resulted in reversion of 
the staining pattern for HDL from the AgNO3-injected mice to that 
seen with control HDL (Figure 4A, lower row). This suggests that 
removal of proteoglycans from the cell surface–associated ECM 
allows HDL from AgNO3-injected mice to contact the plasma 
membrane. Digestion of the ECM with chondroitin ABC lyase and 
heparitinase also restored the ability of HDL from AgNO3-injected 
mice to mediate cholesterol efflux (Figure 4B) and to inhibit Saa3 
gene expression (Figure 4C).
Figure 5. HDL from AgNO3-injected SAA-DKO mice does not colocalize with the adipocyte cell surface, while HDL from AgNO3-injected C57BL/6 mice 
does. HDL from PBS- and AgNO3-injected C57BL/6 and SAA-DKO mice was labeled with DiI (red). 3T3-L1 adipocytes were exposed to these HDL prepara-
tions as described in the legend to Figure 4. Original magnification, ×400. HDL from AgNO3-injected SAA-DKO mice exhibited much less colocalization with 
the adipocyte cell surface than HDL from AgNO3-injected C57BL/6 mice. Representative fluorescence images of 3 independent experiments are shown.
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digestion (Figure 6A, second and third row). This suggests that 
enriching HDL with SAA allows the lipoprotein to be trapped at 
the adipocyte cell surface and prevents the DiI from entering cells. 
Prior digestion of proteoglycans in the adipocyte matrix restored 
the ability of SAA2-HDL to mediate cholesterol efflux (Figure 6B) 
and to inhibit Saa3 gene expression (Figure 6C). These enzymes 
could potentially digest cell surface receptors and thereby affect 
palmitate-induced cell signaling. However, treatment of adipo-
cytes with these enzymes did not affect palmitate-induced inflam-
matory gene expression (Supplemental Figure 5A). Subsequent 
experiments with either chondroitin ABC lyase or heparitinase 
alone indicated that digestion of the matrix by chondroitinase, but 
not heparitinase, was responsible for this effect (Supplemental Fig-
ure 5B). Since 3T3-L1 adipocytes produce a hyaluronan-rich–asso-
ciated ECM (51), we also digested the ECM with hyaluronidase. 
HDL labeled with DiI from AgNO3-injected SAA-DKO mice 
showed a different pattern of staining. Similar to control HDL 
from PBS-injected C57BL/6 and SAA-DKO mice (Figure 5, first 
and third row), HDL labeled with DiI from AgNO3-injected SAA-
DKO mice showed no colocalization with cell surface–associated 
ECM (Figure 5, fourth row), whereas HDL labeled with DiI from 
AgNO3-injected C57BL/6 mice colocalized with cell surface–asso-
ciated ECM (Figure 5, second row). This suggests that the absence 
of SAA in HDL from AgNO3-injected mice prevents the HDL from 
binding to proteoglycans associated with the cell surface. The DiI 
in HDL that is devoid of SAA is thus able to directly contact the 
plasma membrane of adipocytes and enter the cytoplasm.
The pattern of staining of SAA2-HDL labeled with DiI 
more closely resembled that seen in HDL labeled with DiI from 
AgNO3-injected C57BL/6 mice, both before and after enzyme 
Figure 6. SAA-enriched HDL colocalizes with the adipocyte cell surface. (A) Control HDL, which was reisolated from conditioned media from cells not 
transduced with lentivirus, and SAA2-HDL, which was reisolated from conditioned media from cells transduced with a lentivirus-encoding mouse SAA2.1 
protein were labeled with DiI (red). 3T3-L1 adipocytes were exposed to these HDL preparations and stained as described in the legend to Figure 4. Original 
magnification, ×400. SAA2-HDL colocalized with cell surface–associated ECM staining. Pretreatment of adipocytes with chondroitin ABC lyase and hepar-
itinase prior to exposure of SAA2-HDL resulted in a similar distribution of dye to that seen with control HDL. (B and C) Representative fluorescence images 
of 3 independent experiments are shown. After predigestion of the proteoglycans of 3T3-L1 adipocytes with chondroitin ABC lyase and heparitinase for 
1 hour, exposure to SAA2-HDL (50 μg protein/ml) for 6 hours resulted in a restoration of cholesterol efflux (B) and Saa3 gene expression (C) toward that 
seen with control HDL. Data represent mean ± SD. Data are representative of at least 3 independent experiments. *P < 0.001 vs. SAA2-HDL. ANOVA and 
Bonferroni post-hoc test.
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To prevent SAA in HDL binding to the proteoglycans asso-
ciated with the cell surface, we chemically modified the argin-
ine and lysine residues of apolipoprotein in HDL from AgNO3- 
injected mice. SAA1/2 have glycosaminoglycan binding domains 
(23). The negative charge of glycosaminoglycans in proteogly-
cans provides electrostatic attraction for cationic arginine and 
lysine residues in SAA. To test whether modification of arginine 
and lysine residues of SAA in HDL would inhibit HDL binding 
to the ECM of adipocytes, lysine and arginine groups in SAA-
containing HDL from AgNO3-injected mice were modified by 
reductive methylation and cyclohexanedione treatment, respec-
tively. Modified DiI-labeled HDL from AgNO3-injected C57BL/6 
Predigestion of the matrix with hyaluronidase also was shown not 
to be responsible for these effects (Supplemental Figure 5B). These 
results suggest that HDL containing SAA, which contains known 
proteoglycan binding domains (23, 49), binds to chondroitin-sul-
fate proteoglycans associated with the surface of adipocytes and 
may not be able to adequately contact the plasma membrane. This 
absence of contact could underlie the diminished capacity of SAA-
containing HDL to facilitate cholesterol efflux. The observation 
that colocalization was disrupted by enzymatic digestion of proteo-
glycans on the adipocyte cell surface before exposing cells to HDL 
labeled with DiI from AgNO3-injected C57BL/6 mice or SAA2-
HDL labeled with DiI provides further support for this notion.
Figure 7. HDL from moder-
ately inflamed obese mice 
loses its antiinflammatory 
effect on adipocytes and 
colocalizes with ECM in AT. 
(A) 3T3-L1 adipocytes were 
preexposed for 6 hours to 
the indicated concentrations 
of HDL, which was isolated 
from the plasma of Ldlr−/− 
mice fed chow or HFHSC 
diets for 20 weeks (n = 5). 
After that, adipocytes were 
treated as per the legend to 
Figure 1 for measurement of 
Saa3, Ccl2, Il1β, and Il6 gene 
expression. (B) Epididymal 
fat isolated from C57BL/6 
mice fed chow or HFHSC 
diets for 20 weeks was 
stained with Movat’s penta-
chrome stain and analyzed 
by IHC using anti–apoA-I 
and anti-SAA antibodies (B, 
n = 9). SAA colocalized with 
apoA-I in the ECM (blue stain 
with Movat’s) of ATs from 
mice fed the HFHSC diet. 
Tissues were photographed 
using microscopy. Original 
magnification, ×60.  
Data represent mean ± SD. 
*P < 0.001 vs. chow. ANOVA 
and Bonferroni post-hoc  
test for A, and Student t  
test for B.
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Dysfunctional HDL is found in modestly inflamed obese mice and 
in human subjects with SLE and inflammation. To determine whether 
HDL isolated from subjects with more modest and pathophysi-
ologically relevant degrees of inflammation also were impaired 
with respect to inhibition of palmitate-induced inflammatory gene 
expression in adipocytes, we chose to apply our findings to in vivo 
animal and human clinical situations. To this end, we studied HDL 
from obese mice fed a high-fat, high-sucrose, cholesterol-contain-
ing diet (HFHSC diet) that had evidence of both AT and systemic 
mice showed reduced colocalization with cell surface–associ-
ated ECM (Supplemental Figure 6, second row), compared with 
unmodified DiI-labeled HDL from AgNO3-injected mice (Sup-
plemental Figure 6, first row).
Collectively, these results imply that SAA in HDL plays an 
important role in reducing HDL’s antiinflammatory function via 
blocking the access of HDL to the plasma membrane, thereby lim-
iting cholesterol efflux and maintaining higher levels of LR choles-
terol and TLR4 in these rafts.
Figure 8. Loss of antiinflam-
matory effect on adipocytes of 
HDL from SLE patients with high 
CRP and SAA levels. (A–G) HDL 
was isolated from plasma of SLE 
patient (n = 18) and tested for 
their antiinflammatory effect on 
Saa3 and Ccl2 gene expression, as 
well as cholesterol efflux. Linear 
regression relationships among 
Saa3 and Ccl2 gene expression, 
plasma SAA, CRP levels, and per-
centage of cholesterol efflux were 
plotted using Pearson correlation 
coefficient. (H) Subjects were 
arbitrarily divided into those with 
lower (<10 mg/l) and higher (>10 
mg/l) CRP levels for comparison 
of their HDL to inhibit Saa3 gene 
expression. Data represent mean ± 
SD. Student t test.
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ure 7A, bottom 4 panels), plasma SAA (Supplemental Figure 7B, bot-
tom 4 panels), or CRP levels (Supplemental Figure 7B top 4 panels) 
— indicating that our findings are independent of plasma lipid and 
lipoprotein levels. Also, there was no significant correlation between 
the extent of HDL oxidation and its ability to inhibit chemotactic fac-
tor gene expression or stimulate cholesterol efflux, nor did the extent 
of HDL oxidation correlate with the plasma inflammatory markers 
SAA and CRP (Supplemental Figure 8). These findings imply that 
inflammatory environments such as seen with obesity in mice or SLE 
play an important role in impairing the antiinflammatory properties 
of HDL and that the SAA content of the HDL particle, but not its oxi-
dative status, appears to be operative in vivo.
Discussion
We previously have shown that HDL from healthy human subjects 
inhibits palmitate-induced inflammation in differentiated 3T3-L1 
adipocytes (16). In the present study, we extend these findings to 
show that HDL from mice with either severe or modest degrees of 
systemic inflammation, or HDL from modestly inflamed human 
subjects, loses some of these antiinflammatory properties. More-
over, this loss of antiinflammatory function relates to the ability of 
the specific HDL preparation to influence the cholesterol content 
of LRs in the adipocyte plasma membrane by facilitating choles-
terol efflux. In addition, SAA, an HDL apolipoprotein that increases 
during both acute and chronic inflammation, plays a major role in 
rendering HDL dysfunctional in both mice and humans.
Our previous studies demonstrated an important role for plasma 
membrane cholesterol in determining the susceptibility of adipo-
cytes to palmitate-induced inflammation. Strategies that reduced 
plasma membrane cholesterol — such as preexposure of cells to 
either HDL from normal healthy human subjects or apoA-I, or expo-
sure to mβCD — were associated with a reduction in the expression 
of inflammatory genes (16). Conversely, increasing plasma mem-
brane cholesterol by exposure of cells to cholesterol-loaded mβCD 
had the opposite effect (16). We also previously showed that changes 
in membrane cholesterol were accompanied by parallel changes in 
the generation of ROS and that ROS play an important role in gene 
expression (16). We now extend these findings to demonstrate that 
the loss of antiinflammatory properties of various HDL preparations 
from inflamed mice or humans is less effective at all these functions 
than control HDL and that these HDL preparations are no longer 
protective against palmitate-induced inflammation.
Why does the cholesterol content of these plasma mem-
brane domains appear to regulate the inflammatory response 
in adipocytes? TLR density has been proposed to increase with 
increased cholesterol content of plasma membranes of macro-
phages, rendering these cells more susceptible to TLR agonists 
that are ubiquitous in the environment (54). It is conceivable that 
similar changes in adipocytes account for the apparent correla-
tion between membrane cholesterol content and inflammatory 
response, as suggested by our findings in this study. It also is pos-
sible that amplification of the innate immune response by a path-
way requiring metabolism of saturated fatty acids to ceramide and 
activation of PKC-ζ/mitogen–activated protein kinases is required 
for these effects, as has been reported in macrophages (55).
Why is the membrane cholesterol content of adipocytes not 
adequately reduced after exposure of cells to HDL isolated from 
inflammation, and HDL from human subjects with SLE. HDL iso-
lated from male mice fed a HFHSC diet for 20 weeks had high lev-
els of SAA in their HDL compared with chow-fed control mice (26.2 
± 5.2 μg/mg vs. 175.5 ± 43.8 μg/mg HDL protein, chow vs. HFHSC, 
n = 5). Control human HDL and HDL from control Ldlr–/– mice were 
able to inhibit palmitate-induced inflammatory gene expression 
in 3T3-L1 adipocytes, while HDL from the obese HFHSC-fed ani-
mals lost its ability to block inflammatory gene expression (Figure 
7A). However, the extent of oxidation of apoA-I, measured by mass 
spectrometry (MS) as chlorinated tyrosine and oxidized methion-
ine, was not significantly changed between control HDL and HDL 
isolated from plasma of AgNO3-injected mice (chlorinated tyrosine 
71–58 ± 8 μmol/mol vs. 62 ± 10 μmol/mol apoA-I; oxidized methion-
ine 218–131 ± 47 mmol/mol vs. 158 ± 60 mmol/mol apoA-I, PBS vs. 
AgNO3, n = 4) or plasma of mice fed a HFHSC (chlorinated tyrosine 
71–60 ± 6 μmol/mol vs. 59 ± 9 μmol/mol apoA-I; oxidized methion-
ine 218–168 ± 35 mmol/mol vs. 147 ± 45 mmol/mol apoA-I, chow vs. 
HFHSC, n = 5). These results imply that the oxidation of apoA-I is 
not a major contributor to the generation of the dysfunctional HDL 
in these mouse models. To determine whether SAA-containing HDL 
might be trapped in the adipocyte ECM in vivo, we performed IHC 
on gonadal ATs from C57BL/6 mice fed either a chow or HFHSC 
diet for 20 weeks. Chow-fed mice demonstrated little apoA-I, SAA, 
or ECM staining (blue with Movat’s pentachrome stain). Conversely, 
C57BL/6 mice fed the HFHSC diet demonstrated increased staining 
for both apoA-I and SAA, which appeared to have a similar pattern 
of localization with each other and with the ECM (Figure 7B). These 
findings are consistent with our in vitro observations of SAA-con-
taining HDL binding to the adipocyte cell surface–associated ECM.
To extend our findings to human subjects, we isolated HDL 
from human subjects with SLE with various degrees of systemic 
inflammation as assessed by standard inflammatory markers and 
the SLE Disease Activity Index (SLEDAI; Supplemental Table 1). 
HDL isolated from 10 healthy human control subjects all inhib-
ited palmitate-induced inflammatory gene expression (data not 
shown). However, HDL from some SLE patients demonstrated a 
reduced antiinflammatory effect. Interestingly, the extent of HDL 
dysfunction as assessed by its inability to inhibit palmitate-induced 
Saa3 and Ccl2 gene expression positively correlated with the level of 
the circulating inflammatory markers SAA and C-reactive protein 
(CRP) (Figure 8, A–D). Circulating levels of SAA are a reflection of 
SAA-HDL, since most SAA is transported in plasma on HDL (24, 
25). HDL samples that were most dysfunctional with respect to inhi-
bition of Saa3 and Ccl2 gene expression (i.e., those with high SAA 
levels) were least able to stimulate cholesterol efflux (Figure 8E). A 
similar inverse relationship between the ability of HDL to stimulate 
cholesterol efflux from adipocytes were observed with CRP (Fig-
ure 8F) and HDL’s inability to inhibit palmitate-induced Saa3 gene 
expression (Figure 8G). When SLE patients were arbitrarily divided 
into those with CRP values above and below 10 mg/l, HDL from 
subjects with the higher CRP values demonstrated a significant loss 
in its ability to inhibit Saa3 gene expression compared with HDL 
from subjects with the lower CRP values (Figure 8H).
Plasma lipoprotein and lipid concentrations did not correlate 
with HDL function, as assessed by its ability to inhibit inflammatory 
gene expression in adipocytes (Supplemental Figure 7A, top 4 pan-
els) — nor did it correlate with cholesterol efflux (Supplemental Fig-
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thus precluding it from adequately interacting with the plasma mem-
brane and facilitating cholesterol efflux. This notion is supported by 
our findings with respect to the effect of the SAA content on choles-
terol efflux from adipocytes, discussed earlier.
Since SAA only accounts for part of the loss of the anti-
inflammatory effect of HDL, it is of considerable interest to know 
what other factors might be involved. Since oxidative stress can 
accompany inflammation (64, 65), it is possible that oxidation 
of apoA-I also accounts in part for the impaired ability of HDL to 
facilitate efflux. MPO targets apoA-I for site-specific oxidation in 
human subjects with rheumatoid arthritis (66) and in atheroscle-
rotic lesions (36). Moreover, HDL from atherosclerotic humans 
have impaired ABCA1-mediated cholesterol efflux and enhanced 
MPO-mediated apoA-I oxidation (34). Interestingly, the presence 
of SAA on HDL has been reported to impair HDL’s antioxidative 
functionality (40). However, we were not able to find evidence of 
oxidized apoA-I in HDL from obese mice with modest degrees of 
inflammation, nor were we able to find any correlations between 
measures of HDL oxidation and inhibition of inflammatory gene 
expression or inflammatory markers in subjects with SLE. These 
findings suggest that oxidative modification of HDL is not a major 
contributor to HDL dysfunction under these conditions.
Our findings have potentially important implications for clini-
cal disorders characterized by inflammation, especially those asso-
ciated with chronic inflammatory states such as SLE, rheumatoid 
arthritis, obesity, and cardiovascular disease (CVD). McMahon et al. 
showed that HDL from subjects with rheumatoid arthritis and a large 
proportion of patients with SLE had a reduced ability to inhibit LDL 
oxidation, which is a measure of HDL’s antiinflammatory potential 
(22). Since the degree of inflammation varies widely in patients with 
SLE, we chose to evaluate whether the extent of inflammation in 
our SLE subjects was a determinant of the ability of HDL to inhibit 
palmitate-induced inflammation in adipocytes. Our findings indi-
cate that the ability of HDL to inhibit palmitate-induced expression 
of Saa3 and Ccl2 indeed correlated with circulating levels of CRP 
and SAA in the SLE patients, both markers of the extent of systemic 
inflammation. Plasma SAA levels are largely reflective of HDL-SAA 
levels (24, 25). These findings are consistent with our findings using 
mouse HDL, which indicate an important role for SAA in determin-
ing the ability of HDL to exert antiinflammatory functions on adi-
pocytes. They also are consistent with a recent study in which IL-6 
receptor blockade in patients with rheumatoid arthritis resulted 
in marked reduction in CRP, which was accompanied by a parallel 
reduction in the content of SAA-containing HDL, without a change 
in HDL-cholesterol levels (67). Thus, SAA-HDL might be a useful 
biomarker for the antiinflammatory properties of HDL. Other con-
ditions in which HDL is likely to be dysfunctional are the metabolic 
syndrome and type 2 diabetes, both of which are characterized by 
low HDL cholesterol levels and systemic inflammation. SLE subjects 
with high CRP values had substantially higher BMIs than those with 
lower CRP values. Therefore, we cannot exclude the possibility that 
obesity contributed to the HDL dysfunction in this group of patients. 
It also is conceivable that the inability of HDL to suppress inflamma-
tion in AT could lead the production of additional cytokines by AT, 
thereby fueling a cycle in which some of the deleterious effects of 
inflammation could be propagated, thus playing a causal role in the 
inflammation associated with the metabolic syndrome. Future stud-
acutely inflamed mice? One possibility relates to the SAA content of 
HDL under inflammatory conditions. SAA is the major acute-phase 
reactant in mammals (23). The constitutive form, SAA4, is unaf-
fected by inflammation, while SAA1.1 and SAA2.1 in mice and SAA2 
and SAA1 in humans are produced mainly by the liver in response 
to inflammatory stimuli. SAA also is produced by extrahepatic cells 
such as adipocytes, macrophages, and enterocytes (23, 56). Tissue 
expression of all inducible forms of SAA increases dramatically in 
response to acute inflammatory stimuli in both humans and mice, 
returning to baseline by approximately 72 hours (23). However, in 
chronic inflammatory states associated with obesity, the metabolic 
syndrome, and type 2 diabetes, circulating SAA levels are modestly 
and chronically elevated (57–60). SAA1, -2, and -4 are transported 
in plasma mainly bound to HDL (24, 26, 61) and are not transported 
free in plasma. Our data indicate that the presence of SAA in HDL 
is an important determinant of HDL’s ability to suppress inflam-
mation in adipocytes. HDL that was enriched in SAA did not blunt 
palmitate-induced inflammatory gene expression in our adipocyte 
assay to the same extent as control HDL. Conversely, HDL isolated 
from AgNO3-injected mice deficient in both SAA1.1 and SAA2.1 
(SAA-DKO mice) had stronger antiinflammatory properties than 
HDL from WT AgNO3-injected mice, and HDL isolated several 
days after the injection of AgNO3 — by which time SAA levels had 
returned toward normal — functioned like control HDL. These loss- 
and gain-of-function experiments provide strong evidence for an 
important role of SAA in determining the antiinflammatory prop-
erties of HDL, although other factors clearly are involved, as well. 
It also is unclear why SAA-containing HDL is unable to suppress 
inflammation to the extent seen with control HDL. One obvious 
possibility is that SAA-containing HDL is dysfunctional with respect 
to cholesterol efflux, which would in turn be a major determinant 
of plasma membrane cholesterol content. Although some studies 
show that lipid-free SAA can facilitate lipid efflux (62, 63) and that 
the sterol efflux capacity of HDL from hepatocytes improves during 
inflammation (63), others have shown that SAA-containing HDL 
inhibits cholesterol efflux and reverse cholesterol transport from 
macrophages (26–28). Our observations with SAA-depleted and 
SAA-enriched HDL support the proposal that the SAA content of 
HDL is an important determinant of its ability to facilitate choles-
terol efflux from the plasma membrane of adipocytes.
Important clues to why the presence of SAA on HDL inhibits its 
ability to adequately facilitate cholesterol efflux are derived from our 
studies in which we observed colocalization of HDL from AgNO3- 
injected mice and SAA2-HDL with cell surface–associated ECM of 
adipocytes, whereas normal HDL did not colocalize with the adipo-
cyte cell surface. Colocalization of both these forms of SAA-enriched 
HDL could be inhibited by prior enzymatic digestion of extracellular 
proteoglycans, suggesting a critical role for cell surface–associated 
proteoglycans in these interactions. Moreover, the observation that 
HDL from inflamed SAA-DKO mice, as well as HDL from inflamed 
mice in which the positively charged lysine and arginine residues 
were neutralized, also failed to colocalize with the cell surface of adi-
pocytes invokes a critical role for SAA in the interaction of HDL with 
proteoglycans associated with the adipocyte cell surface. SAA is well 
known to have proteoglycan binding domains (23, 49). These obser-
vations suggest that interaction of SAA on HDL with proteoglycans 
at the cell surface of adipocytes leads to trapping of the lipoprotein, 
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10 with low CRP. Plasma samples were stored in aliquots at –80°C. 
Plasma lipid and lipoprotein levels were measured enzymatically in 
the core laboratories of the University of Washington’s Nutrition Obe-
sity Research Center, and free cholesterol and total phospholipid were 
measured enzymatically in the University of Washington’s Northwest 
Lipid Metabolism and Diabetes Research Laboratories.
Adipocyte cell culture and RT-PCR. 3T3-L1 murine preadipocytes, 
obtained from the American Type Tissue Culture Collection, and 
MEFs, isolated from embryos of C57BL/6 mice at 13.5 days postco-
itum (a gift from Carol B. Ware, University of Washington), were 
propagated and differentiated according to standard procedures (77). 
Human SGBS (a gift from Martin Wabitsch, University of Ulm, Ulm, 
Germany) were grown and differentiated as described previously (42). 
Fully differentiated adipocytes were pretreated with 50 μg protein/ml 
or the indicated concentration of HDL protein or apoA-I for 6 hours, 
and then washed 3 times with PBS. Adipocytes then were incubated 
for 24 hours with 250 μmol/l palmitate for measurement of gene 
expression by reverse transcription PCR (RT-PCR). RT-PCR was per-
formed using the TaqMan Master kit (Applied Biosystems) in the ABI 
prism 7900HT system (75, 78). Saa3, Ccl2, Il1β, Il6, and Gapdh prim-
ers with FAM probes were obtained from Applied Biosystems (Assay-
on-Demand). Each sample was analyzed in triplicate and normalized 
using GAPDH as control. Some samples also were normalized with a 
second housekeeping gene, β-2-microglobulin (B2m) and showed sim-
ilar results (Supplemental Figure 9).
Cholesterol efflux from adipocytes. To measure the cholesterol 
efflux capacity of HDL, fully differentiated 3T3-L1 adipocytes were 
radiolabeled by incubating the cells with 1 μCi/ml 3H-cholesterol 
(PerkinElmer) in DMEM/1 mg/ml fatty acid–free BSA overnight. 
Cells were then washed and incubated with DMEM/fatty acid–free 
BSA without or with 50 μg protein/ml or the indicated concentration 
of HDL protein for 6 hours at 37°C. Medium was collected and filtered, 
and the 3H-cholesterol content of medium and cells was quantified. 
The fraction of total 3H-cholesterol released into the medium was cal-
culated as (counts in the medium with HDL – counts in the medium 
without HDL)/(counts in the medium + counts in the cells ) × 100.
Measurement of plasma membrane cholesterol and LRs. Cellular 
membranes were isolated from 3T3-L1 adipocytes as described pre-
viously (79). Membrane preparations were resuspended in 100 μl 
of ethanolic potassium hydroxide (1 mol/l), and cholesterol-d7 was 
added as the internal standard. After saponification, the lipid fraction 
was extracted from the membrane preparations with hexane and dried 
under nitrogen gas. Total cholesterol levels were determined after 
derivatization using liquid chromatography electrospray ionization 
tandem MS (LC-MS/MS), as described previously (16, 80).
LRs in plasma membranes of 3T3-L1 adipocytes were quantified 
as described previously (79) using Alexa Fluor 594–conjugated CTB 
(Molecular Probes, Invitrogen). Briefly, cultured 3T3-L1 adipocytes 
were incubated with 1 μg/ml of Alexa Fluor 594–conjugated CTB 
for 15 minutes at 4°C. After washing twice with cold PBS, cells were 
fixed in 4% paraformaldehyde for 20 minutes at 4°C. CTB staining of 
fixed cells was analyzed by FACS (FACSCanto, BD Biosciences), as 
described previously (16).
Detergent-free LR fractionation. LR and non-LR fractions from 
adipocytes were obtained by OptiPrep (Sigma-Aldrich) gradient 
centrifugation using a detergent-free protocol, as described previ-
ously (79). Briefly, the cell pellet was homogenized in buffer (250 
ies that investigate the relationships among obesity, inflammation, 
and HDL function are likely to provide additional insights into the 
importance of HDL as a cardioprotective and antiinflammatory lipo-
protein. Strategies to inhibit such a cycle has obvious translational 
implications for the management of chronic inflammatory disorders 
such as SLE, rheumatoid arthritis, the metabolic syndrome, and type 
2 diabetes — disorders in which inflammation has been suggested to 
play a role in the pathogenesis of CVD.
It is possible that the negative results of recent clinical trials in 
which drug-induced increases in HDL-cholesterol did not result in 
improved clinical outcomes (68–70) might relate to HDL-choles-
terol being the wrong metric by which to assess HDL. For example, 
recent studies suggest that HDL-mediated sterol efflux from mac-
rophages is a better marker of CVD risk than HDL-cholesterol (71, 
72). Future clinical studies should include the antiinflammatory 
capacity of HDL. Moreover, new biomarkers such as SAA-HDL, 
which reflects HDL function, may prove to be better metrics of 
CVD risk than HDL-cholesterol per se.
Methods
Reagents. Palmitate (16:0) (Sigma-Aldrich) was conjugated with albu-
min, as described previously (73). Briefly, palmitate was first dissolved 
in NaOH (100 mmol/l) to a final concentration of 100 mmol/l, and 
conjugated with fatty acid–free albumin (Sigma-Aldrich) at a molar 
ration of 3:1 (palmitate/albumin). Alexa Fluor 594–conjugated CTB 
was purchased from Invitrogen. HDL (d = 1.063–1.210 g/ml) was 
isolated from plasma of mice, healthy human volunteers, and SLE 
patients by ultracentrifugation (45, 74). Human apoA-I was purchased 
from Academy Bio-medical Co. Murine and human SAA protein con-
centrations were measured by ELISA kits (Immunology Consultants 
Laboratory Inc.). Anti-GAPDH antibody was purchased from Cell Sig-
naling Technology (5174S, 1:1,000).
Animals, diets, and human subjects. To determine whether acute 
inflammation influenced HDL’s ability to inhibit palmitate-induced 
expression of chemotactic factors in adipocytes, 10-week-old male 
C57BL/6 mice or SAA-DKO mice (43) were i.p. injected with AgNO3 
(0.5 ml, 0.015 mg/ml) or PBS. After 24 hours, plasma was obtained 
for isolation of HDL by ultracentrifugation (45, 74). To determine the 
effect of more moderate chronic inflammation on HDL function, HDL 
was isolated from mice that had been made obese by consumption of 
an obesogenic, proinflammatory diet. For this purpose, 10-week-old 
male LDL receptor-deficient (Ldlr−/−) mice on a C57BL/6 background 
or WT C57BL/6 mice were fed a HFHSC diet (35.5% calories as fat 
and 36.6% as carbohydrate, 0.15% added cholesterol; F4997, BioServ) 
for 20 weeks, which resulted in obesity, insulin resistance, and both 
AT and systemic inflammation (75). Chow-fed Ldlr–/– or C57BL/6 mice 
were used as controls. SAA-DKO, Ldlr–/–, and some C57BL/6 mice 
were from an in-house breeding colony. Other C57BL/6 mice were 
purchased from The Jackson Laboratory. At sacrifice, HDL was iso-
lated from plasma by ultracentrifugation. HDL particle concentration 
was measured by calibrated ion mobility analysis (76).
To test whether HDL from human subjects with chronic inflam-
mation was dysfunctional, HDL was isolated from 18 subjects with 
SLE recruited from outpatient clinics at the University of Washing-
ton Hospital and Harborview Medical Center. All met the American 
College of Rheumatology’s criteria for this diagnosis. From a cohort 
of SLE patients, we randomly selected 8 patients with high CRP and 
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7.4% formaldehyde (Sigma-Aldrich) were added to 1 mg/ml of HDL. 
Additional 5 μl aliquots of 7.4% formaldehyde were added every 6 
minutes for 30 minutes. For a more extensive modification, another 
1 mg of sodium borohydride was added after 30 minutes, and addi-
tions of formaldehyde were continued at 6-minute intervals for a 
total 60 minutes. The reaction was stopped by dialysis against 0.15 
mol/l NaCl, 0.01%EDTA, pH 7.0.
Immunofluorescence and IHC. DiI-labeled HDL was generated by 
incubation of HDL with the red dye, DiI (Molecular Probes, Invitro-
gen). Briefly, 300 μl of DiI in dimethyl sulfoxide (3 mg/ml) was added 
slowly to 5 ml HDL (2 mg protein/ml) in 0.1 M phosphate-buffered 
saline, pH 7.4. The mixture was agitated gently and incubated for 8 
hours at 37°C under nitrogen in the dark. DiI-labeled HDL was reiso-
lated by ultracentrifugation (d = 1.063–1.21 g/ml).
To evaluate the localization of DiI and the ECM in adipo-
cytes, 3T3-L1 adipocytes were cultured on glass cover slips, and 
DiI-labeled HDL preparations were added for 6 hours, then 
fixed in 2% formalin for 5 minutes. The ECM of adipocytes was 
stained using a cell-impermeable Alexa Fluor 594–conjugated 
WGA (Molecular Probes, Invitrogen), which selectively binds to 
N-acetylglucosamine and N-acetylneuraminic acid residues on 
plasma membranes (85). For some experiments, the ECM was 
digested prior to adding DiI-labeled HDL by incubation of the 
cells with chondroitin ABC lyase (Proteus vulgaris, Seikagaku 
Corp.) (0.1 unit/ml) in 0.1 M Tris, 0.1 M acetate (pH 7.3), and hep-
aritinase (Flauobacterium heparinum, Seikagaku Corp.) (10 mU/
ml) for 1 hour at 37°C. To determine whether DiI-labeled HDL 
binds to hyaluronan produced by 3T3-L1 adipocytes (51), the cell- 
associated ECM was digested prior to adding HDL by incubation 
with Streptomyces hyaluronidase (200 mU/ml, Sigma-Aldrich) for 
1 hour at 37°C. Nuclei were counterstained with DAPI. Cells were 
photographed using an Axioskop fluorescent microscope (Zeiss).
For IHC, ATs were fixed in 10% formalin for immunohistochem-
ical staining with apoA-I (Rockland Immunochemicals, 600-101-196, 
1:4000) or SAA (R&D Systems, AF2948, 1:25) antibodies, as described 
previously (86). Images were morphometrically analyzed using Image 
Pro Plus 6.0 (Media Cybernetics).
Statistics. Statistical significance was determined with SPSS (Win-
dows version 19) or OriginPro software (version 8.6; Origin Labora-
tory). All data are shown as means ± SD of 3 independent experiments 
performed in triplicate. Student t test was used to detect differences 
within groups when applicable (2-tailed and unpaired). One-way 
ANOVA was used to compare differences among all groups, and Bon-
ferroni post-hoc testing was used to detect differences among mean 
values of the groups. Pearson coefficient was used for linear regression 
analysis. P < 0.05 was considered significant.
Study approval. All experimental procedures in mice were 
undertaken with approval from the Institutional Animal Care and 
Use Committee of the University of Washington (protocol nos. 
3104-01 and 4237-01).
All human subjects provided written informed consent and 
authorization for blood draws and release of medical information 
(protocol no. 39712).
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FCD, and WRO conducted experiments. MCD, FCD, MEG, and 
mmol/l sucrose, 1 mmol/l EDTA, 500 mmol/l sodium bicarbonate, 
pH 11). After centrifugation (1,000 × g, 10 minutes), the postnuclear 
supernatant fraction was added to 60% OptiPrep to make 35% Opti-
Prep (final concentration), overlaid on a discontinuous gradient of 
5%–35% OptiPrep and centrifuged at 350,000 g in a Beckman NVT 
65.2 rotor for 90 minutes at 4°C. Nine 0.5-ml fractions were collected 
and subjected to immunoblotting using antibodies against TLR4 
(Cell Signaling Technology, 14358; 1:1,000) and caveolin-1 (Cell Sig-
naling Technology, 3238; 1:1,000). To evaluate the specificity of the 
TLR4 antibody, immunoblot analysis was performed using fat pads 
from TLR4-deficient mice and control mice (Supplemental Figure 
10). This antibody nicely detected TLR4 protein in AT from control 
but not TLR4-deficient mice.
Quantification of ROS. ROS generation by adipocytes was assessed 
as CM-H2DCFDA (Molecular Probes, Invitrogen) fluorescence, which 
was monitored by FACS (FACSCanto, BD Biosciences), as described 
previously (73, 79).
Quantification of oxidative modification in HDL by MS. HDL isolated 
by sequential ultracentrifugation from control mice, AgNO3-injected 
mice, mice fed a HFHSC diet, and from healthy subjects or SLE patients 
was supplemented with 100 μmol/l diethylenetriaminepentaacetic 
acid, 100 μmol/l butylated hydroxytoluene, and a protease inhibitor 
cocktail (Sigma-Aldrich) to inhibit artifactual oxidation during isola-
tion. An aliquot (10 μg protein) of HDL was reduced with dithiothreitol 
(DTT), alkylated with iodoacetamide, and then digested with trypsin 
and Glu-C as previously described (81). HDL digests was analyzed by 
nano–LC/selected reaction monitoring–MS/MS (nano–LC/SRM-MS/
MS) on a Thermo TSQ Vantage coupled to a Waters nanoACQUITY 
UltraPerformance liquid chromatography (nano-UPLC) system for 
quantification of methionine and tryptophan oxidation in apoA-I as 
described previously (34, 36). The same approach was applied to quan-
tify the levels of chlorinated Tyr192 and oxidized Met148 in human 
HDL isolated from healthy subjects and SLE patients (34).
Preparation of SAA-enriched HDL. To make SAA-enriched HDL, 
we first transduced lentivirus-encoding mouse SAA2.1 under the 
cytomegalovirus (CMV) promoter into HEK 293 cells. After confirm-
ing stable transduction using GFP protein, human HDL was added 
to either SAA2.1-transduced or mock-transduced cells at a final con-
centration of 0.3 mg/ml. Twenty-four hours later, conditioned media 
were collected and the HDL was reisolated by ultracentrifugation. We 
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cates reisolated HDL with conditioned media from cells transduced 
by lentivirus encoding SAA2.1 protein; mock-HDL indicates reisolated 
HDL exposed to cells transduced by mock lentivirus; and control-HDL 
represents HDL reisolated from conditioned media from cells not 
transduced with lentivirus.
Chemical modification of HDL. Selective chemical modification 
of lysine and arginine residues in HDL was performed as described 
previously for LDL (82–84). Cyclohexanedione was used to modify 
arginine residues and reductive methylation for lysine modifica-
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was dialyzed in 0.1 mol/l sodium borate buffer (pH 8.1) and incu-
bated with 0.15 mol/l 1,2-cyclohexadione (Sigma-Aldrich) in 0.1 
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